This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc Health (TDOC) Q2 Earnings Top Estimates on Lower Expenses
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 results reflect improving access fees and other revenues coupled with lower expenses.
Compared to Estimates, Teladoc (TDOC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Teladoc (TDOC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teladoc (TDOC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 9.09% and 0.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will High Tech Costs Hurt Teladoc Health (TDOC) in Q2 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q2 results are likely to have benefited from improved access fees and growing BetterHelp membership, partly offset by elevated technology and development expenses.
Teladoc (TDOC) & Microsoft Partner to Reduce Administrative Woes
by Zacks Equity Research
Teladoc (TDOC) collaborates with Microsoft, enabling automatic clinical documentation with the help of AI.
Icon PLC (ICLR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed the most recent trading day at $25.35, moving +1.56% from the previous trading session.
Teladoc (TDOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $24.55 in the latest trading session, marking a -0.73% move from the prior day.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $22.57 in the latest trading session, marking a +0.04% move from the prior day.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $25.25, marking a -0.16% move from the previous day.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $24.48, marking a -1.61% move from the previous day.
Teladoc (TDOC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $24.91 in the latest trading session, marking a -1.7% move from the prior day.
Why Is Viatris (VTRS) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $24.79, marking a +1.27% move from the previous day.
Why Is Teladoc (TDOC) Down 16.5% Since Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Hold on to Teladoc Health (TDOC) Stock for Now?
by Zacks Equity Research
Teladoc Health's (TDOC) cash-generating abilities are boosted by the growing number of visits and memberships.
Teladoc Health (TDOC) Shares Up 5% Since Q1 Earnings Release
by Zacks Equity Research
Teladoc Health's (TDOC) Q1 results reflect solid chronic care product revenues and improving access fees and other revenues.
3 Steps to Indentifying the Market Environment
by Andrew Rocco
In order to be profitable, investors must know what type of environment they are in. Currently, quality growth stocks are driving the market higher.
Teladoc (TDOC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 27.45% and 1.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Rising Expenses Hurt Teladoc Health's (TDOC) Q1 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) first-quarter results are likely to reflect growth in Access Fees revenues and total visits.
Analysts Estimate Pediatrix Medical Group (MD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Teladoc (TDOC): Can Its 5.7% Jump Turn into More Strength?
by Zacks Equity Research
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.